For research use only. Not for therapeutic Use.
Asenapine maleate(CAS 85650-56-2) is an atypical antipsychotic developed for the treatment of schizophrenia and acute mania associated with bipolar disorder. Preliminary data indicate that it has minimal anticholinergic and cardiovascular side effects, as well as minimal weight gain. FDA approved thisderug in August 2009.
| Catalog Number | I000516 |
| CAS Number | 85650-56-2 |
| Synonyms | Org 5222; Org5222; Org-5222; HSDB 8061; HSDB-8061; HSDB8061; Asenapine; Asenapine maleate; trade names Saphris and Sycrest.;(3aS,12bS)-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole maleate |
| Molecular Formula | C17H16ClNO.C4H4O4 |
| Purity | ≥95% |
| Target | 5-HT Receptor |
| Solubility | Soluble in DMSO, not in water |
| Storage | 3 years -20C powder |
| Related CAS | 65576-45-6(free base) |
| Overview of Clinical Research | Asenapine maleate is an alpha adrenergic receptor antagonist and a dopamine receptor antagonist developed by AbbVie. |
| IUPAC Name | (Z)-but-2-enedioic acid;(2S,6S)-9-chloro-4-methyl-13-oxa-4-azatetracyclo[12.4.0.02,6.07,12]octadeca-1(18),7(12),8,10,14,16-hexaene |
| InChI | InChI=1S/C17H16ClNO.C4H4O4/c1-19-9-14-12-4-2-3-5-16(12)20-17-7-6-11(18)8-13(17)15(14)10-19;5-3(6)1-2-4(7)8/h2-8,14-15H,9-10H2,1H3;1-2H,(H,5,6)(H,7,8)/b;2-1-/t14-,15-;/m1./s1 |
| InChIKey | GMDCDXMAFMEDAG-CHHFXETESA-N |
| SMILES | CN1C[C@@](C2=CC=CC=C2OC3=CC=C(Cl)C=C34)([H])[C@]4([H])C1.O=C(O)/C=CC(O)=O |
| Reference | 1: Managuli RS, Gourishetti K, Shenoy RR, Koteshwara KB, Reddy MS, Mutalik S. Preclinical pharmacokinetics and biodistribution studies of asenapine maleate using novel and sensitive RP-HPLC method. Bioanalysis. 2017 Jul 24. doi: 10.4155/bio-2017-0069. [Epub ahead of print] PubMed PMID: 28737445.<br /> |
